New drug duo shows promise for hard-to-treat cancers
NCT ID NCT03725436
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new drug called ALRN-6924 combined with the chemotherapy paclitaxel in 28 adults with advanced solid tumors that had spread or couldn't be removed by surgery, including a type of breast cancer. The main goal was to find the safest dose and check for side effects. Researchers also looked at whether the tumors shrank or disappeared after treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Can a protein calm the immune System's overreaction to cancer treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a tracer that hunts unstable iron light up hidden tumors?